Examination of Direct-Acting Antiviral treatment for hepatitis C on prognosis and recurrence of hepatocellular carcinoma

Examination of impact on prognosis and recurrence Direct-Acting Antiviral for hepatitis C-related hepatocellular carcinoma after Treatment. - Examination of impact on prognosis and recurrence DAA for hepatitis C-related hepatocellular carcinoma after Treatment.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038109

Enrollment

300

Registered

2019-09-26

Start date

2019-09-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathological or abdominal ultrasonography (including contrast imaging with sonazoid), contrast-enhanced CT, EOB-MRI, diagnosed as a liver malignant tumor. 2) Patients who have been confirmed that there is no hepatocellular carcinoma by contrast-enhanced CT or EOB-MRI within 3 months after surgery after hepatectomy or RFA as the first treatment. 3) A patient with Child-Pugh classification A before hepatectomy or RFA. 4) DAA of non-administration is the first case of HCC. 5) In case of DAA is administered, wether of HCC may be the first or recurrence.

Exclusion criteria

Exclusion criteria: 1) Patients who have been refused participation in this study. 2) Child-Pugh before liver resection or RFA is B or C. 3) Cases with distant metastasis before HCC treatment.

Design outcomes

Primary

Measure	Time frame
Prognosis after treatment for hepatocellular carcinoma	—

Countries

Japan

Contacts

Public ContactOchi Hironori

Matsuyama Red Cross Hospital Center for Liver-Billiary-Pancreas

hironori19810211@gmail.com0899241111

Outcome results